Novira Therapeutics Announces Presentation of Phase Ia Safety and Pharmacokinetic Data for NVR 3-778

By WebmasterNovember 10, 2014November 1st, 2024No Comments

Novira Therapeutics Announces Presentation of Phase Ia Safety and Pharmacokinetic Data for NVR 3-778
Read more here

Previous PostRelmada Therapeutics Receives Health Canada Clearance to Commence First Clinical Study of d-Methadone
Next PostRelmada Therapeutics Appoints Michael Becker as Senior Vice President of Finance and Corporate Development